Oct 03rd 2013 - Edison Investment Research today published a report on oncolytics biotech inc entitled "Promising Lung Cancer Data". In summary, the report says:
Promising tumour response data from two Phase II studies of Reolysin in squamous cell carcinoma of the lung (SCC lung) and in non-small cell lung cancer (NSCLC) support further randomised trials in these indications. Oncolytics has an ongoing Phase II trial in SCC and adenocarcinoma of the lung. Data from the lead Phase II squamous cell head and neck cancer trial are expected soon.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »